By Colin Kellaher
Kenvue has struck a cooperation agreement with Starboard Value, averting a proxy fight with the activist investment firm.
Kenvue on Wednesday said it has added three new board members, including Starboard chief Jeffrey Smith, who has expressed disappointment with the consumer health company's management and share-price performance.
Smith last year said that Kenvue, the maker of Band-Aids and Tylenol that was spun out from Johnson & Johnson in 2023, should drill down on fixing its underperforming skin health and beauty segment and on improving the company's marketing strategy.
Starboard last month nominated a slate of four director candidates, including Smith, in a bid to reconstitute Kenvue's board.
Kenvue said it added Smith, along with independent directors Sarah Hofstetter and Erica Mann, to its board, and that Starboard will withdraw its nominees and vote its shares in favor of the Skillman, N.J., company's board slate at this year's annual meeting. Hofstetter is president of e-commerce insights platform Profitero, while Mann is a former head of Bayer's consumer-health division.
Kenvue said its board will temporarily expand to 14 directors from 11 before being reduced to 13 directors at the annual meeting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 05, 2025 08:45 ET (13:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。